The cost for each drug can easily exceed $1000 per month
Survodutide , another GLP-1/glucagon dual agonist from Boehringer Ingelheim, is advancing through clinical trials
One simple approach: try starting meals with protein and fats, then add carbohydrates in a way that works for you
For anyone who wants to try GLP1s treatment without locking themselves into a contract, MEDVi hits the right balance between affordability and the level of medical support that makes a real difference, especially in the early months of treatment
Projected commercial pricing When Eli Lilly eventually brings retatrutide to market, likely in late 2027 or 2028, analysts project a list price of $1,000 to $1,500 per month based on comparable GLP-1 medications like Mounjaro and Ozempic
In a phase 2 clinical trial, retatrutide achieved mean adipose tissue reduction of up to 24% over 48 weeks, surpassing existing pharmacological options for obesity treatment (Jastreboff et al., 2023)